News News - 2023 Hummingbird Bioscience Initiates HMBD-001 Phase IB Trials in Australia and Partners with Omico to Accelerate Clinical Development Continue Reading
News News - 2023 Hummingbird Bioscience and Synaffix Enter License Agreement to Develop a Next Generation Antibody Drug Conjugate (ADC) Program Continue Reading
News News - 2022 Caris Life Sciences and Hummingbird Bioscience Enter Into Collaboration to Advance Clinical Development of Anti-HER3 Therapy Continue Reading
HMBD-002 Posters Posters - 2022 Publications & Posters SITC 2022: Anti-VISTA antibody HMBD-002 reprograms tumor associated macrophages and promotes cytotoxic T cell response Continue Reading
HMBD-002 Posters Posters - 2022 Publications & Posters SITC 2022: Trial in Progress: A phase 1 first-in-human study of HMBD-002, an IgG4 monoclonal antibody targeting VISTA, as a monotherapy and combined with pembrolizumab in patients with advanced solid malignancies Continue Reading
News News - 2022 Hummingbird Bioscience Announces Two HMBD-002 Poster Presentations at the Society for Immunotherapy of Cancer 2022 Annual Meeting Continue Reading
News News - 2022 Hummingbird Bioscience to Attend the Credit Suisse 31st Annual Healthcare Conference Continue Reading
News News - 2022 Biomed start-up Hummingbird Bioscience opens new facility to boost its R&D work Continue Reading
